Management of Lisinopril Therapy with Elevated Potassium Levels

Introduction to Lisinopril Management

The American College of Cardiology and American Heart Association recommend that aldosterone antagonists should not be used when potassium is ≥5.0 mEq/L, and that potassium >5.0 mEq/L represents a contraindication 1
The American College of Cardiology and American Heart Association specify that potassium levels >5.5 mEq/L should trigger discontinuation or dose reduction of medications affecting the renin-angiotensin system 2

The American Heart Association notes that a 10-20% increase in serum creatinine can be anticipated when ACE inhibitor therapy is initiated in patients with chronic renal disease, and this is not itself an indication to discontinue treatment 3
The American Heart Association states that the key threshold is whether creatinine rises by >0.5 mg/dL if baseline is <2.0 mg/dL, or >1.0 mg/dL if baseline exceeds 2.0 mg/dL 4

The American College of Cardiology and American Heart Association recommend stopping lisinopril immediately due to the potassium level of 5.5 mEq/L, and restarting only after potassium falls below 5.0 mEq/L 1, 2
Implement dietary potassium restriction to <3 g/day (50-70 mmol/day) 5
Avoid high-potassium foods including bananas, oranges, potatoes, tomatoes, salt substitutes, and certain herbal supplements 5
If on potassium supplements, discontinue them immediately 1

The American College of Cardiology and American Heart Association emphasize that potassium should be less than 5.0 mEq/L before initiating or continuing ACE inhibitor therapy 1, 6
Hyperkalemia can cause life-threatening cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, and cardiac arrest 5

Consider switching to a different antihypertensive class (calcium channel blockers, beta-blockers, or direct vasodilators) that does not affect potassium homeostasis 5
Use newer potassium binders (patiromer or sodium zirconium cyclosilicate) to maintain normokalemia while continuing RAAS inhibition, though this requires specialist consultation 5, 7

The American College of Cardiology and American Heart Association recommend that if you have heart failure with reduced ejection fraction or proteinuric kidney disease, RAAS inhibition provides mortality benefit 1, 6
Aggressive management of hyperkalemia with dietary restriction, diuretic optimization, and potentially newer potassium binders may allow you to continue lisinopril safely 5, 7